SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

RGTI is trending due to a recent surge in quantum computing stocks, fueled by a $5.7 million sale of two quantum computers. Community discussions revolve around the stock's high valuation and potential for a short squeeze, with bullish investors targeting higher prices while bears anticipate a significant correction. The broader context involves the rapidly growing quantum computing sector and its speculative nature.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum (QBTS) is trending amid general excitement in the quantum computing sector, with community members highlighting its potential for energy-efficient solutions. Some traders are discussing potential breakouts and short squeezes, while others compare QBTS to other quantum and AI stocks. Recent news and government initiatives in quantum tech appear to be driving interest.

Rumble, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

Rumble Inc - Ordinary Shares - Class A

Rumble Inc

Rumble is trending due to a new partnership with Perplexity AI, aiming to enhance content discovery and offer a bundled subscription service. The community is buzzing about the potential impact on Rumble's platform and revenue streams, with some speculating about a possible short squeeze given the high short interest and Trump's backing.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IONQ is trending as the quantum computing sector gains momentum, with community members actively discussing its potential and comparing it to other players like $QBTS and $RGTI. Bullish sentiment is fueled by the company's collaborations, and some traders anticipate a short squeeze as the stock approaches all-time highs. Others remain skeptical, pointing to valuation concerns and the long-term horizon for quantum computing commercialization.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is trending as community members discuss the potential impact of recent news, including a private placement, on the stock. Some are optimistic about the company's future and potential government backing, while others express concerns about revenue and valuation, leading to a debate on the stock's prospects. Trading volume and options activity are elevated compared to average levels.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as users highlight its association with weed culture and its potential for growth, drawing comparisons to Bitcoin. Community members emphasize Weedcoin's focus on freedom, natural growth, and cultural connection, promoting it as more than just a cryptocurrency. Discussions also involve community links and contract addresses.

Epsium Enterprise Ltd. operates as a holding company, which engages in import trading and distribution of wines and spirits. It offers a range of products, including Chinese liquor, French cognac, Scottish whisky, fine wines, champagne, and other miscellaneous alcoholic beverages. Its brands include Moutai, Xijiu, Wuliangye, Remy Martin Cognac, Macallan, Cointreau, Piper Heidsieck Champagne, French Fine Wines, Red and White Wines. The company was founded by Son I Tam on March 24, 2020 and is headquartered in Macau.

Epsium Enterprise Ltd. - Ordinary Shares - Class A

Epsium Enterprise Ltd.

Epsium Enterprise Ltd. ($EPSM) is trending due to a volatile trading pattern, marked by frequent trading halts and significant price swings, reminiscent of other high-flying stocks. Community chatter revolves around whether the stock is a pump-and-dump scheme, with some anticipating a massive sell-off while others hope for continued upward momentum. The stock's connection to the Chinese booze market and its small float are also fueling speculation and trading activity.

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

Alto Neuroscience (ANRO) is trending due to its FDA Fast Track designation for ALTO-101, a potential treatment for cognitive impairment associated with schizophrenia, which has no currently approved treatments. The community is actively discussing the stock's potential for significant gains if Phase 2 data is positive, given the unmet medical need and substantial market size. Discussions also include institutional ownership, cash runway, and potential short squeezes.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as investors react to news of a partnership with Corning, anticipating a boost in next-generation battery production and a move closer to commercialization. The community is highly bullish, discussing potential price targets and new partnerships, while also expressing excitement over the company's long-term potential in the solid-state battery sector. Some traders believe this move validates QuantumScape's technology and scaling capabilities, leaving skeptics and short sellers behind.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir ($PLTR) is trending with mixed sentiment after a report highlighted security flaws in a battlefield comms prototype, triggering a community debate. While some see it as a buying opportunity amidst a euphoric bull market, others question its valuation and potential government contract impacts. The community is actively discussing whether to buy the dip or wait for further developments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of CNS Pharmaceuticals, Inc. (CNSP) declined 5% on Friday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://cnspharma.com/ir/press-releases/cns-pharmaceuticals-announces-primary-analysis-of-berubicin-in-second-line-treatment-of-glioblastoma-multiforme-44471506">reported </a>wider losses in the first quarter (Q1).The firm’s net loss for the three months ended March 31, 2025, was approximately $4.3 million, compared to approximately $3.5 million for the comparable period in 2024.The company said the increase in net loss is largely attributable to the costs of data clean-up, preparation, and analysis for the topline primary data release on the Berubicin trial in brain cancer.CNS Pharmaceuticals’ research and development expenses rose to $3.2 million in the quarter, while general and administrative expenses fell marginally to $1.09 million, owing to a decrease in stock-based compensation, marketing, advertising, and insurance expenses.The company ended the quarter with cash of approximately $13.1 million. CNS believes that the cash on hand as of March 31, 2025, in addition to the $5 million raised from a public offering earlier this month, is sufficient to fund planned operations into the second half of 2026.CNS is developing treatments for cancers in the brain and central nervous system. By year-end, the company intends to commence the phase 2 study of its lead program, TPI 287, for treating Glioblastoma Multiforme (GBM). Glioblastoma multiforme (GBM) is the most common form of cancer that originates in the brain.On Stocktwits, retail sentiment around CNSP remained ‘extremely bullish’ over the past 24 hours while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_16_at_9_01_42_AM_png_cf9bcf9c43.webp" alt="CNSP's Sentiment Meter and Message Volume as of 9 a.m. ET on May 16, 2025 | Source: Stocktwits" width="627" height="63"><figcaption>CNSP's Sentiment Meter and Message Volume as of 9 a.m. ET on May 16, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/CNSP">CNSP stock</a> is down by 80% this year and over 99% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-ceo-to-step-down/chiw5m5Rbno">Novo Nordisk CEO Lars Jørgensen Steps Down Amid Challenges, Retail Chatter Spikes</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

CNS Pharmaceuticals Stock Declines On Wider Q1 Loss: But Retail Stays Unmoved

The company intends to commence the phase 2 study of its lead program, TPI 287, to treat Glioblastoma Multiforme (GBM) by year-end.

Equity

Why CNS Pharmaceuticals (CNSP) Stock Is Up 86%

CNS Pharmaceuticals shares are trading higher by 76% Wednesday morning. The stock faces potential delisting for not meeting Nasdaq's $1.00 bid price.
read more...

What's Going On With CNS Pharmaceuticals Stock Tuesday?

CNS Pharmaceuticals entered into a exclusive license agreement with Cortice Biosciences.
read more...

CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements

Lead program, Berubicin, successfully passed pre-planned interim futility analysis milestone with recommendation from DSMB to proceed without modification in potentially pivotal GBM studyBerubicin...

CNS Pharmaceuticals to Present at Two Investor Conferences in April

HOUSTON, TX / ACCESSWIRE / April 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ('CNS' or the 'Company'), a biopharmaceutical company specializing in the development of novel treatments for...

CNS Pharmaceuticals prices $4M public offering

CNS Pharmaceuticals prices $4M public offering...

CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering

HOUSTON, TX / ACCESSWIRE / January 29, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ('CNS' or the 'Company'), a biopharmaceutical company specializing in the development of novel treatments for...

Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors

Highly accomplished biopharmaceutical industry executive with successful track record in the commercialization and launch of drugs in varied therapeutic areas including oncology, neurology, and...

CNS Pharmaceuticals completes planned enrollment in study of berubicin in GBM

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)

HOUSTON, TX / ACCESSWIRE / January 17, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ('CNS' or the 'Company'), a biopharmaceutical company specializing in the development of novel treatments for...

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

Cns Pharmaceuticals Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

CNSP
Cns Pharmaceuticals Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest CNSP News

CNSP Cns Pharmaceuticals Inc